Alendronate affects osteoblast functions by crosstalk through ephrinB1-EphB

E. Shimizu, J. Tamasi, Nicola Partridge

Research output: Contribution to journalArticle

Abstract

Bisphosphonates are therapeutic agents in the treatment of post-menopausal osteoporosis. Although they have been associated with delayed healing in injured tissues, inappropriate femoral fractures, and osteonecrosis of the jaw (ONJ), the pathophysiological mechanisms involved are not clear. Our hypothesis is that alendronate, a member of the N-containing bisphosphonates, indirectly inhibits osteoblast function through the coupling of osteoclasts to osteoblasts by ephrinB-EphB interaction. We found that alendronate increased gene and protein expression of ephrinB1 and EphB1, as well as B3, in femurs of adult mice injected with alendronate (10 μg/100 g/wk) for 8 weeks. Alendronate suppressed the expression of bone sialoprotein (BSP) and osteonectin in both femurs and bone marrow osteoblastic cells of mice. After elimination of pre-osteoclasts from bone marrow cells, alendronate did not affect osteoblast differentiation, indicating the need for pre-osteoclasts for alendronate's effects. Alendronate stimulated EphB1 and EphB3 protein expression in osteoblasts, whereas it enhanced ephrinB1 protein in pre-osteoclasts. In addition, a reverse signal by ephrinB1 inhibited osteoblast differentiation and suppressed BSP gene expression. Thus, alendronate, through its direct effects on the pre-osteoclast, appears to regulate expression of ephrinB1, which regulates and acts through the EphB1, B3 receptors on the osteoblast to suppress osteoblast differentiation.

Original languageEnglish (US)
Pages (from-to)268-274
Number of pages7
JournalJournal of Dental Research
Volume91
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Alendronate
Osteoblasts
Osteoclasts
Integrin-Binding Sialoprotein
Diphosphonates
EphB1 Receptor
Bone Marrow Cells
Femur
Osteonectin
Gene Expression
Postmenopausal Osteoporosis
Proteins
Femoral Fractures
Osteonecrosis
Jaw

Keywords

  • bone biology
  • cell biology
  • gene expression
  • osteoblast(s)
  • osteoclast(s)
  • osteonecrosis

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

Alendronate affects osteoblast functions by crosstalk through ephrinB1-EphB. / Shimizu, E.; Tamasi, J.; Partridge, Nicola.

In: Journal of Dental Research, Vol. 91, No. 3, 03.2012, p. 268-274.

Research output: Contribution to journalArticle

@article{a7a2fed0d64542469071bb52743b668a,
title = "Alendronate affects osteoblast functions by crosstalk through ephrinB1-EphB",
abstract = "Bisphosphonates are therapeutic agents in the treatment of post-menopausal osteoporosis. Although they have been associated with delayed healing in injured tissues, inappropriate femoral fractures, and osteonecrosis of the jaw (ONJ), the pathophysiological mechanisms involved are not clear. Our hypothesis is that alendronate, a member of the N-containing bisphosphonates, indirectly inhibits osteoblast function through the coupling of osteoclasts to osteoblasts by ephrinB-EphB interaction. We found that alendronate increased gene and protein expression of ephrinB1 and EphB1, as well as B3, in femurs of adult mice injected with alendronate (10 μg/100 g/wk) for 8 weeks. Alendronate suppressed the expression of bone sialoprotein (BSP) and osteonectin in both femurs and bone marrow osteoblastic cells of mice. After elimination of pre-osteoclasts from bone marrow cells, alendronate did not affect osteoblast differentiation, indicating the need for pre-osteoclasts for alendronate's effects. Alendronate stimulated EphB1 and EphB3 protein expression in osteoblasts, whereas it enhanced ephrinB1 protein in pre-osteoclasts. In addition, a reverse signal by ephrinB1 inhibited osteoblast differentiation and suppressed BSP gene expression. Thus, alendronate, through its direct effects on the pre-osteoclast, appears to regulate expression of ephrinB1, which regulates and acts through the EphB1, B3 receptors on the osteoblast to suppress osteoblast differentiation.",
keywords = "bone biology, cell biology, gene expression, osteoblast(s), osteoclast(s), osteonecrosis",
author = "E. Shimizu and J. Tamasi and Nicola Partridge",
year = "2012",
month = "3",
doi = "10.1177/0022034511432170",
language = "English (US)",
volume = "91",
pages = "268--274",
journal = "Journal of Dental Research",
issn = "0022-0345",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Alendronate affects osteoblast functions by crosstalk through ephrinB1-EphB

AU - Shimizu, E.

AU - Tamasi, J.

AU - Partridge, Nicola

PY - 2012/3

Y1 - 2012/3

N2 - Bisphosphonates are therapeutic agents in the treatment of post-menopausal osteoporosis. Although they have been associated with delayed healing in injured tissues, inappropriate femoral fractures, and osteonecrosis of the jaw (ONJ), the pathophysiological mechanisms involved are not clear. Our hypothesis is that alendronate, a member of the N-containing bisphosphonates, indirectly inhibits osteoblast function through the coupling of osteoclasts to osteoblasts by ephrinB-EphB interaction. We found that alendronate increased gene and protein expression of ephrinB1 and EphB1, as well as B3, in femurs of adult mice injected with alendronate (10 μg/100 g/wk) for 8 weeks. Alendronate suppressed the expression of bone sialoprotein (BSP) and osteonectin in both femurs and bone marrow osteoblastic cells of mice. After elimination of pre-osteoclasts from bone marrow cells, alendronate did not affect osteoblast differentiation, indicating the need for pre-osteoclasts for alendronate's effects. Alendronate stimulated EphB1 and EphB3 protein expression in osteoblasts, whereas it enhanced ephrinB1 protein in pre-osteoclasts. In addition, a reverse signal by ephrinB1 inhibited osteoblast differentiation and suppressed BSP gene expression. Thus, alendronate, through its direct effects on the pre-osteoclast, appears to regulate expression of ephrinB1, which regulates and acts through the EphB1, B3 receptors on the osteoblast to suppress osteoblast differentiation.

AB - Bisphosphonates are therapeutic agents in the treatment of post-menopausal osteoporosis. Although they have been associated with delayed healing in injured tissues, inappropriate femoral fractures, and osteonecrosis of the jaw (ONJ), the pathophysiological mechanisms involved are not clear. Our hypothesis is that alendronate, a member of the N-containing bisphosphonates, indirectly inhibits osteoblast function through the coupling of osteoclasts to osteoblasts by ephrinB-EphB interaction. We found that alendronate increased gene and protein expression of ephrinB1 and EphB1, as well as B3, in femurs of adult mice injected with alendronate (10 μg/100 g/wk) for 8 weeks. Alendronate suppressed the expression of bone sialoprotein (BSP) and osteonectin in both femurs and bone marrow osteoblastic cells of mice. After elimination of pre-osteoclasts from bone marrow cells, alendronate did not affect osteoblast differentiation, indicating the need for pre-osteoclasts for alendronate's effects. Alendronate stimulated EphB1 and EphB3 protein expression in osteoblasts, whereas it enhanced ephrinB1 protein in pre-osteoclasts. In addition, a reverse signal by ephrinB1 inhibited osteoblast differentiation and suppressed BSP gene expression. Thus, alendronate, through its direct effects on the pre-osteoclast, appears to regulate expression of ephrinB1, which regulates and acts through the EphB1, B3 receptors on the osteoblast to suppress osteoblast differentiation.

KW - bone biology

KW - cell biology

KW - gene expression

KW - osteoblast(s)

KW - osteoclast(s)

KW - osteonecrosis

UR - http://www.scopus.com/inward/record.url?scp=84856899193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856899193&partnerID=8YFLogxK

U2 - 10.1177/0022034511432170

DO - 10.1177/0022034511432170

M3 - Article

VL - 91

SP - 268

EP - 274

JO - Journal of Dental Research

JF - Journal of Dental Research

SN - 0022-0345

IS - 3

ER -